HALO · Earnings event · Q2 2026 · archived
Halozyme Therapeutics (HALO) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $2.28 vs estimate $1.82 (+25.5%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $1.82 | $2.28 | +25.5% |
| Revenue (2026-06-30) | — | $481.0M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated HALO Sell at 6.7/10. After the Q2 2026 report, the verdict moved to Buy (Wait) at 6.7/10.
Healthcare context
HALO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $11.20B
- P/E (fwd)
- 9.5
- P/E (ttm)
- 28.9
- 52-week range
- $61.23–$104.78
- Off 52-week high
- 6.2%
- RSI (14)
- 80
- Volume vs avg
- 0.71×
- Engine score
- 6.5/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.